Literature DB >> 10699955

Defective Jak-STAT signal transduction pathway in melanoma cells resistant to growth inhibition by interferon-alpha.

A Pansky1, P Hildebrand, E Fasler-Kan, L Baselgia, S Ketterer, C Beglinger, M H Heim.   

Abstract

Advanced malignant melanoma is an aggressive malignancy with poor prognosis. Current therapeutic strategies have a modest success rate. The most promising treatment consists of a combination of chemotherapy with interferon-alpha, but complete response rates remain less than 15%. Interferon-alpha is also effective in adjuvant therapy for non-advanced melanoma treated surgically. The molecular mechanisms leading to loss of growth restraints and gain of growth-promoting functions during carcinogenesis of malignant melanoma are not understood in detail. Here, we studied 9 human melanoma cell lines with regard to growth inhibition by interferon-alpha and defects in intracellular signal transduction through the Jak-STAT pathway. In 3 cell lines, we found a complete loss of growth restraint by interferon-alpha. In all of them, different components of the Jak-STAT pathway were defective. Since signal transduction through the Jak-STAT pathway is necessary for antiviral and antiproliferative effects of interferons, we conclude that defects in this pathway may be one of the mechanisms that lead to cancer progression through loss of growth-restraining functions. Moreover, our results indicate that a subgroup of melanomas could be completely resistant to interferon-alpha and should therefore not be treated with this cytokine. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10699955     DOI: 10.1002/(sici)1097-0215(20000301)85:5<720::aid-ijc20>3.0.co;2-o

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  24 in total

1.  Phaeosphaeride A, an inhibitor of STAT3-dependent signaling isolated from an endophytic fungus.

Authors:  Katherine N Maloney; Wenshan Hao; Jun Xu; Jay Gibbons; John Hucul; Deborah Roll; Sean F Brady; Frank C Schroeder; Jon Clardy
Journal:  Org Lett       Date:  2006-08-31       Impact factor: 6.005

2.  Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapy.

Authors:  Lina Such; Fang Zhao; Derek Liu; Beatrice Thier; Vu Thuy Khanh Le-Trilling; Antje Sucker; Christoph Coch; Natalia Pieper; Sebastian Howe; Hilal Bhat; Halime Kalkavan; Cathrin Ritter; Robin Brinkhaus; Selma Ugurel; Johannes Köster; Ulrike Seifert; Ulf Dittmer; Martin Schuler; Karl S Lang; Thomas A Kufer; Gunther Hartmann; Jürgen C Becker; Susanne Horn; Soldano Ferrone; David Liu; Eliezer M Van Allen; Dirk Schadendorf; Klaus Griewank; Mirko Trilling; Annette Paschen
Journal:  J Clin Invest       Date:  2020-08-03       Impact factor: 14.808

3.  STAT 5a expression in various lesions of the breast.

Authors:  Gary L Bratthauer; Brian L Strauss; Fattaneh A Tavassoli
Journal:  Virchows Arch       Date:  2005-08-19       Impact factor: 4.064

4.  Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines.

Authors:  Sateesh Krishnamurthy; Toru Takimoto; Ruth Ann Scroggs; Allen Portner
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

5.  IRF-4 and c-Rel expression in antiviral-resistant adult T-cell leukemia/lymphoma.

Authors:  Juan Carlos Ramos; Phillip Ruiz; Lee Ratner; Isildinha M Reis; Carlos Brites; Celia Pedroso; Gerald E Byrne; Ngoc L Toomey; Valentine Andela; Edward W Harhaj; Izidore S Lossos; William J Harrington
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

6.  The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouse.

Authors:  Gregory B Lesinski; Mirela Anghelina; Jason Zimmerer; Timothy Bakalakos; Brian Badgwell; Robin Parihar; Yan Hu; Brian Becknell; Gerard Abood; Abhik Ray Chaudhury; Cynthia Magro; Joan Durbin; William E Carson
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

7.  Modulation of SOCS protein expression influences the interferon responsiveness of human melanoma cells.

Authors:  Gregory B Lesinski; Jason M Zimmerer; Melanie Kreiner; John Trefry; Matthew A Bill; Gregory S Young; Brian Becknell; William E Carson
Journal:  BMC Cancer       Date:  2010-04-14       Impact factor: 4.430

8.  Bortezomib pre-treatment prolongs interferon-alpha-induced STAT1 phosphorylation in melanoma cells.

Authors:  Gregory B Lesinski; Kristen Benninger; Melanie Kreiner; Megan Quimper; Gregory Young; William E Carson
Journal:  Cancer Immunol Immunother       Date:  2009-04-26       Impact factor: 6.968

9.  Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway.

Authors:  Hannes Steiner; Sonia Godoy-Tundidor; Hermann Rogatsch; Andreas P Berger; Dietmar Fuchs; Barbara Comuzzi; Georg Bartsch; Alfred Hobisch; Zoran Culig
Journal:  Am J Pathol       Date:  2003-02       Impact factor: 4.307

Review 10.  Hope and fear for interferon: the receptor-centric outlook on the future of interferon therapy.

Authors:  Serge Y Fuchs
Journal:  J Interferon Cytokine Res       Date:  2013-04       Impact factor: 2.607

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.